Sequence information
Variant position: 201 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 955 The length of the canonical sequence.
Location on the sequence:
KSSSKDSRPSQAAGDNQGDE
A KEQTFSGGTSQDTKASESSK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KSSSKDSRPSQAAGDNQGDEA KEQTFSGGTSQDTKASESSK
Mouse KSSSKDSRPSQAAGDNQGDEA KEQTFSGGTSQDIKGSESSK
Rat KSSSKDSRPSQAAGDNQGDEA KEQTFSGGTSQDIKGSESSK
Xenopus laevis KSSSKDSRPSQAAGDNQGDEA KEQTFSGGTSQDIKGSESSK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
2 – 955
Thyroid hormone receptor-associated protein 3
Region
117 – 559
Disordered
Compositional bias
187 – 241
Polar residues
Modified residue
220 – 220
Phosphoserine
Modified residue
221 – 221
N6-acetyllysine; alternate
Cross
202 – 202
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO1); alternate
Cross
202 – 202
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Cross
215 – 215
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Cross
221 – 221
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Literature citations
Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators.
Ito M.; Yuan C.-X.; Malik S.; Gu W.; Fondell J.D.; Yamamura S.; Fu Z.-Y.; Zhang X.; Qin J.; Roeder R.G.;
Mol. Cell 3:361-370(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; PROTEIN SEQUENCE OF 490-500; TISSUE SPECIFICITY; IDENTIFICATION IN TRAP COMPLEX; VARIANT VAL-201;
Submission
Mural R.J.; Istrail S.; Sutton G.G.; Florea L.; Halpern A.L.; Mobarry C.M.; Lippert R.; Walenz B.; Shatkay H.; Dew I.; Miller J.R.; Flanigan M.J.; Edwards N.J.; Bolanos R.; Fasulo D.; Halldorsson B.V.; Hannenhalli S.; Turner R.; Yooseph S.; Lu F.; Nusskern D.R.; Shue B.C.; Zheng X.H.; Zhong F.; Delcher A.L.; Huson D.H.; Kravitz S.A.; Mouchard L.; Reinert K.; Remington K.A.; Clark A.G.; Waterman M.S.; Eichler E.E.; Adams M.D.; Hunkapiller M.W.; Myers E.W.; Venter J.C.;
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT VAL-201;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT VAL-201;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.